3,933 Shares of AbbVie Inc. $ABBV Purchased by StoneRidge PMG Advisors LLC

Posted by Brenda Bartman on Nov 9th, 2026

StoneRidge PMG Advisors LLC purchased a new stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,933 shares of the company’s stock, valued at approximately $1,029,000.

Other large investors have also recently bought and sold shares of the company. Burk Holdings LLC acquired a new position in shares of AbbVie during the 2nd quarter worth approximately $30,000. Marquette Asset Management LLC boosted its holdings in shares of AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after buying an additional 48 shares during the last quarter. Principia Wealth Advisory LLC boosted its holdings in shares of AbbVie by 38.9% in the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after buying an additional 44 shares during the last quarter. IMG Wealth Management Inc. boosted its holdings in shares of AbbVie by 3,060.0% in the 2nd quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock valued at $40,000 after buying an additional 153 shares during the last quarter. Finally, Tacita Capital Inc bought a new position in shares of AbbVie in the second quarter valued at $42,000. 70.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ABBV has been the topic of a number of recent analyst reports. Argus boosted their target price on shares of AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. Barclays upped their price target on shares of AbbVie from $300.00 to $325.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 21st. Sanford C. Bernstein reiterated a “market perform” rating and issued a $275.00 price target on shares of AbbVie in a research note on Monday, November 2nd. Bank of America reissued a “buy” rating on shares of AbbVie in a research report on Tuesday, September 8th. Finally, Cantor Fitzgerald lifted their price objective on shares of AbbVie from $290.00 to $325.00 and gave the company an “overweight” rating in a research report on Monday, November 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $297.46.

Read Our Latest Report on AbbVie

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: AbbVie’s third-quarter results beat expectations, with revenue of $17.4 billion, and the company raised its full-year adjusted earnings outlook. The earnings report has strengthened the growth case for the shares. AbbVie stock climbs as Q3 earnings fuel growth case
Positive Sentiment: A licensing agreement with Nxera Pharma for an EP4 agonist gives AbbVie another potential inflammatory bowel disease treatment candidate. The deal may add to its pipeline as investors assess the durability of its newer growth drivers. Nxera licenses EP4 agonist to AbbVie
Positive Sentiment: AbbVie recently reached a fresh high following its earnings beat and a dividend increase, while analysts remain broadly optimistic. This supports investor interest in the stock as a defensive healthcare name. AbbVie’s new growth engines face another test
Negative Sentiment: AbbVie’s shares have already climbed substantially and are near their 52-week high, leaving less room for disappointment. Humira’s decline also means the company must continue demonstrating that newer products can sustain growth. The one thing to settle before buying AbbVie stock

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.06% of the stock is owned by corporate insiders.

AbbVie Stock Up 0.1%

NYSE:ABBV opened at $291.51 on Monday. The stock’s 50 day moving average price is $271.98 and its two-hundred day moving average price is $239.04. The firm has a market capitalization of $515.27 billion, a price-to-earnings ratio of 50.17, a P/E/G ratio of 1.32 and a beta of 0.20. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $302.93.

AbbVie (NYSE:ABBV – Get Free Report) last issued its earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, topping the consensus estimate of $3.73 by $0.09. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The company had revenue of $17.40 billion during the quarter, compared to the consensus estimate of $17.32 billion. During the same period in the previous year, the company posted $1.86 EPS. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. Equities research analysts expect that AbbVie Inc. will post 13.99 EPS for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be issued a dividend of $1.82 per share. The ex-dividend date of this dividend is Friday, January 15th. This represents a $7.28 annualized dividend and a yield of 2.5%. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s payout ratio is 119.10%.

About AbbVie

(Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas.

Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.

AbbVie was established in 2013 as a spin-off from Abbott Laboratories and is headquartered in North Chicago, Illinois.